Luxturna Gene Therapy: How It Works, Results and What to Expect

Luxturna gene therapy is a one-time treatment for eligible people with vision loss caused by confirmed biallelic RPE65 gene mutations and sufficient remaining retinal cells. It delivers a functional copy of the RPE65 gene beneath the retina, with the goal of improving the retina’s ability to respond to light.

Overview: What Is Luxturna Gene Therapy?

Luxturna gene therapy is a prescription gene therapy for a rare group of inherited retinal diseases caused by disease-causing changes in both copies of the RPE65 gene. Its generic name is voretigene neparvovec. These conditions can cause severe night blindness, reduced side vision, and progressive loss of vision from childhood or later in life.

The therapy supplies a working copy of the RPE65 gene to certain retinal cells. This helps the visual cycle, a process the retina uses to respond to light. Luxturna is not a cure for every form of inherited vision loss, and it cannot restore retinal cells that have already been lost. It is intended for people whose testing confirms the specific genetic cause and who have enough viable retinal cells to potentially benefit.

Because inherited retinal conditions may look similar but have different genetic causes, a careful evaluation by an inherited-retinal-disease specialist is important. Genetic counselling can also help patients and families understand the diagnosis, inheritance pattern, and implications for relatives.

How Luxturna Works in the Retina

The retina is the light-sensitive layer at the back of the eye. It contains photoreceptor cells, including rods that are particularly important for seeing in dim light. The retinal pigment epithelium, a supporting cell layer beneath the photoreceptors, plays an essential part in processing vitamin A-derived molecules used in vision.

In people with biallelic RPE65 mutations, the visual cycle is disrupted. Although photoreceptor cells may still be present, they may not respond normally to light. Luxturna uses a modified adeno-associated virus, or AAV, as a delivery vehicle. The virus has been altered so that it does not cause disease.

During surgery, the treatment is placed into the space beneath the retina. The vector enters retinal pigment epithelial cells and delivers a functional RPE65 gene. Those cells can then produce the RPE65 protein needed for the visual cycle. The treatment does not alter a person’s inherited DNA throughout the body and is not passed to future children.

Luxturna is sometimes discussed alongside other approaches being studied for inherited retinal disease, such as gene-specific treatments, cell-based therapies, and retinal prosthetic technologies. However, these approaches are not interchangeable, and suitability depends on the individual diagnosis and stage of retinal disease.

Who May Be a Candidate for Luxturna?

A person may be considered for Luxturna when genetic testing confirms pathogenic or likely pathogenic mutations in both copies of the RPE65 gene. This is often described as biallelic RPE65-associated retinal dystrophy. The condition may be diagnosed as a form of Leber congenital amaurosis or retinitis pigmentosa, but the genetic result is central to determining whether Luxturna is appropriate.

Patients must also have enough viable retinal cells. Retinal specialists assess this using detailed eye examinations and imaging, often including optical coherence tomography, fundus photography, and tests of retinal function. Visual-field testing and low-light mobility assessment may also be used to document how vision affects daily activities.

Age alone does not determine eligibility. Treatment decisions are individualized and consider the genetic diagnosis, remaining retinal structure, current vision, general health, eye anatomy, and ability to undergo retinal surgery and follow-up. An active eye infection or significant eye inflammation generally needs to be addressed before treatment.

Family members may benefit from genetic counselling, particularly when there is a known inherited retinal condition. A specialist can explain what a genetic result means, whether relatives should consider testing, and how to plan ongoing eye care.

What Happens During the Luxturna Procedure and Recovery?

Luxturna is delivered through a specialized retinal operation called pars plana vitrectomy. The procedure is usually performed in an operating room by a vitreoretinal surgeon. Each eye is treated separately, with the second eye generally treated on a different day after an interval determined by the treating team.

First, the surgeon removes the gel-like vitreous from inside the eye. A very small amount of Luxturna is then injected beneath the retina, creating a temporary small retinal elevation, often called a bleb. This placement allows the gene therapy to reach the target retinal pigment epithelial cells. The surgical team provides instructions about anaesthesia, fasting, medicines, and transportation home.

Corticosteroids are commonly prescribed around the time of treatment to help reduce inflammation. The exact regimen is individualized by the treating clinician. After surgery, patients need scheduled eye examinations to monitor healing, eye pressure, inflammation, and retinal status.

Recovery experiences vary. Mild discomfort, redness, blurred vision, floaters, and light sensitivity can occur soon after surgery. Vision may fluctuate while the eye heals, and functional changes may become noticeable over weeks to months. Patients should follow activity restrictions and positioning advice provided by their surgeon, including any guidance about air or gas used during the operation.

How Well Does Luxturna Work?

Clinical studies of Luxturna showed that many treated participants improved in functional vision, particularly their ability to navigate in low-light conditions. This is meaningful because reduced night vision and difficulty moving safely through dim environments are common features of RPE65-associated retinal disease.

Some people also experience improvements in light sensitivity, visual fields, or everyday visual functioning. However, the degree of improvement differs from person to person. Luxturna may improve usable vision but does not necessarily produce normal vision, and visual acuity on a standard eye chart may change less than low-light navigation ability.

Benefits depend partly on how much functioning retinal tissue remains before treatment. The treatment cannot replace photoreceptors that are no longer present, which is one reason early specialist assessment can be important after a confirmed diagnosis. A retinal specialist can discuss realistic goals based on examination findings and test results.

Assessment before and after treatment usually includes more than one measure of vision. The care team may compare visual acuity, visual fields, retinal imaging, light sensitivity, and the person’s own report of activities such as moving around in low light.

How Long Does Luxturna Last?

Luxturna is designed as a one-time treatment for each eye. Follow-up from clinical studies has shown that improvements in functional vision can persist for several years in many treated people. However, inherited retinal diseases and long-term responses can vary, and the full lifelong duration of benefit is not yet known.

The delivered gene is intended to remain active in treated retinal cells, but Luxturna does not reverse all effects of an inherited retinal disorder. Retinal cells may still change over time because of the underlying condition. Ongoing retinal follow-up is therefore recommended even when vision has improved.

At present, repeat treatment is not routinely established. Decisions about long-term monitoring, additional supportive care, visual rehabilitation, and new treatment opportunities should be made with an inherited-retinal-disease specialist.

What Are the Risks of Luxturna Therapy?

Luxturna involves both gene therapy and retinal surgery, so risks include those related to the medicine, the injection beneath the retina, and vitrectomy. Possible eye-related effects include inflammation, increased eye pressure, cataract development, retinal tears or detachment, macular holes, infection inside the eye, reduced vision, and changes in the retina or cornea. Some complications can be serious and may require additional treatment.

Short-term effects such as eye redness, discomfort, blurred vision, floaters, sensitivity to light, or temporary changes in visual function may occur after surgery. Corticosteroids used around treatment can also have side effects, which should be reviewed with the clinical team.

Patients should contact their eye surgeon promptly for increasing pain, worsening redness, sudden vision loss, a curtain or shadow in vision, new flashes of light, a marked rise in floaters, severe headache, nausea, or any symptom that feels concerning after eye surgery. These symptoms do not always mean a serious complication, but timely assessment is important.

The treating team reviews individual risks before treatment and explains how to prepare for surgery and follow recovery instructions. Reporting all medicines, allergies, prior eye operations, and health conditions helps the team plan care safely.

How Much Does Luxturna Cost and When to Seek Medical Care

The cost of Luxturna can vary substantially by country, healthcare system, hospital, insurance coverage, travel needs, surgical care, testing, and follow-up requirements. A reliable estimate requires an individualized discussion with the treating hospital and, where applicable, the insurer or public health payer. Patients should also ask what services are included, such as genetic testing, retinal imaging, surgery, medicines, follow-up visits, and visual rehabilitation support.

Medical assessment is appropriate for anyone with unexplained night blindness, progressive difficulty seeing in dim light, narrowing side vision, or a family history of inherited retinal disease. Children with poor visual responses, nystagmus, or difficulty functioning in low light should be assessed by an eye specialist without unnecessary delay.

Urgent eye care is needed after retinal surgery for sudden or major deterioration in vision, severe pain, increasing redness, new flashes or floaters, or a dark curtain across the visual field. People with confirmed or suspected RPE65-related disease should be referred to a retinal specialist with experience in inherited retinal disorders rather than assuming that every gene therapy is suitable for their condition.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can support international patients seeking assessment and treatment planning for inherited retinal conditions, including evaluation for Luxturna gene therapy.

Frequently asked questions

What is Luxturna gene therapy used for?

Luxturna is used for people with inherited retinal disease caused by confirmed disease-causing mutations in both copies of the RPE65 gene. The person must also have viable retinal cells, as determined by a specialist eye examination and retinal testing. It is not suitable for all forms of retinitis pigmentosa or all inherited vision loss.

How long does Luxturna last?

Luxturna is given once to each treated eye, and study follow-up has shown that functional vision improvements may persist for years. However, the lifelong duration of benefit is still being studied. Continued follow-up is important because the underlying retinal condition may still change over time.

How much does Luxturna cost?

Luxturna costs vary by country, care setting, insurance or public funding arrangements, surgery, testing, and follow-up care. A treatment center can provide an individualized estimate after confirming eligibility and the planned care pathway. Patients should ask whether genetic testing, medicines, surgery, and follow-up visits are included.

How well does Luxturna work?

Luxturna has improved functional vision for many eligible patients in clinical studies, especially navigation in dim light. The amount of improvement varies and may depend on the condition of the retina before treatment. It may improve useful vision but does not guarantee normal vision or restore retinal cells that have already been lost.

What are the risks of Luxturna therapy?

Risks include inflammation, increased eye pressure, cataract, retinal tears or detachment, infection, and loss or worsening of vision. There are also usual risks associated with retinal surgery and medicines used around the procedure. The retinal surgeon will explain individual risks and the warning symptoms that need urgent review.

Is Luxturna given as an injection into the arm?

No. Luxturna is administered directly beneath the retina during a specialized eye operation. It is not an intravenous infusion, and it is usually delivered to one eye at a time by an experienced vitreoretinal surgeon.

References

• U.S. Food and Drug Administration
• European Medicines Agency
• American Academy of Ophthalmology
• National Eye Institute
• American Society of Retina Specialists

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.